Chasing stocks in an overbought market is dangerous. With that in mind, overbought markets can go higher. These stocks hold the proverbial big risk, big reward handle.
2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
Companies receiving analyst upgrades, downgrades, initiations or other key notes on Tuesday morning include Alcoa, Arch Coal, Baidu, Ciena, JD.com and Vale.
Here are, the 11 top stock picks from the analysts at Merrill Lynch for 2017. Most look well-suited for growth portfolios that have a degree of risk tolerance.
With the Republicans now set to control both Congress and the White House, many on Wall Street feel that there could be far less scrutiny on drug pricing.
Regeneron Pharmaceuticals reported mixed third-quarter financial results before the markets opened on Friday.
Chris Lange Ocular Therapeutix and Regeneron are attempting to develop a sustained release formulation of aflibercept that is suitable for advancement into clinical development.
Chris Lange An RBC report noted that although headline issues such as the Federal Reserve and the election are increasing volatility, four top biotech companies may be a solid play now.
Stocks overall were fractionally higher early on Monday, August 29, 2016. That makes the big percentages gainers and losers and the companies with big headline news stand out even more.
The top analyst upgrades, downgrades and initiations seen on Friday morning include FireEye, Occidental Petroleum, SeaWorld, Teva Pharmaceutical, Windstream and Zynga.
Though these four large cap biotech stocks are cheap relative to the S&P 500, history says they won’t stay that way.
June 22, 2016: Here are four stocks trading with relatively heavy volume among 40 equities making new 52-week lows in Wednesday’s session. NYSE decliners led advancers by 5 to 4 while Nasdaq…
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include ArcelorMittal, Boeing, Intel, Johnson & Johnson, Schlumberger, Yahoo and Vivint Solar.
Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their primary endpoints.
Chris Lange Regeneron Pharmaceuticals saw its shares halted on Wednesday afternoon after a jury ruled in favor of Amgen on a cholesterol drug patent.
